NL-OMON21799招募中不适用
Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoidA phase IIa open label single arm study
MCG0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adult patients with recently diagnosed mild to moderate localized or generalized cutaneous pemphigoid, or patients that were in complete remission without treatment that have a mild-moderate flare-up of the disease.
排除标准
- •Contradiction or known allergy for PDE4 inhibitors.
- •Women of childbearing potential without contraception, women who are pregnant or planning to become pregnant or who are lactating.
研究者
相似试验
进行中（未招募）
1 期
PDE4 inhibitor (apremilast) in pemphigoid.EUCTR2018-002564-10-NLniversitair Medisch Centrum Groningen10
已完成
2 期
Short-term safety, efficacy and mode of action of apremilast in moderate suppurative hidradenitis suppurativa: a randomised double-blind placebo controlled trial.acne ectopicaacne inversa10014982NL-OMON42894Erasmus MC, Universitair Medisch Centrum Rotterdam20
已完成
2 期
Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study.parapemphigus10014982NL-OMON49116niversitair Medisch Centrum Groningen10
已完成
不适用
Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPHJPRN-UMIN000025443ara Medical University200
尚未招募
3 期
Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary SyndromesHeart AttackHeart Disease10082206NL-OMON34504Anthera Pharmaceuticals, Inc576